Get the Stockscreener App
4.99
1.38%
-0.07
Pre-market:
4.98
-0.010
-0.20%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $4.99, with a volume of 2.29M.
It is down -1.38% in the last 24 hours and down -7.93% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
See More
Previous Close:
$5.06
Open:
$5.13
24h Volume:
2.29M
Relative Volume:
1.36
Market Cap:
$1.86B
Revenue:
$10.53B
Net Income/Loss:
$-1.23B
P/E Ratio:
-1.5373
EPS:
-3.246
Net Cash Flow:
$949.99M
1W Performance:
-2.35%
1M Performance:
-7.93%
6M Performance:
-27.79%
1Y Performance:
-16.56%
1-Day Range:
$4.965
$5.166
1-Week Range:
$4.965
$5.325
52-Week Range:
$4.93
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
4.99 | 1.86B | 10.53B | -1.23B | 949.99M | -3.246 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Actinic Keratosis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Almirall, Biofrontera Pharma, Vidac Pharma, Rubedo Life Sciences, Bausch Health, Sandoz Pharma - Barchart.com
TSX Healthcare Stocks: Which Names Are Drawing Market Attention? - Kalkine Media
BHC Q1 2026 Earnings: EPS Surges 12.33% Above Estimates, Shares Edge HigherEarnings Surprise Score - newsline.com
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia - Cantech Letter
Why Bausch Health Companies Inc stock is sliding today - Wealth Awesome
Barclays Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $7 - Moomoo
Is Bausch Health Finally Finding Its Comeback Moment? - Kalkine Media
Bausch Health: Invest In The Short-Term Bonds, Not The Stock (NYSE:BHC) - Seeking Alpha
Valeant Investors Should Get Cert. In PwC Fight, Report Says - Law360
Bausch Health Companies stock (CA0717341071): Canadian pharma name in focus after fresh institutiona - AD HOC NEWS
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Only 217 brands in China hold this mark. Thermage just earned it - Stock Titan
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China - PR Newswire
TSX Pharma Companies Building Regional Healthcare Reach - Kalkine Media
Bausch Health (BHC) director Amy Wechsler granted $250,000 in RSUs - Stock Titan
Bausch Health (NYSE: BHC) grants $250,000 RSU award to director Eiry Roberts - Stock Titan
Bausch Health (NYSE: BHC) director receives $250,000 RSU equity grant - Stock Titan
John Paulson (BHC) receives $250K RSU award and reports large fund holdings - Stock Titan
Bausch Health (BHC) director awarded $250K in RSUs - Stock Titan
Bausch Health (BHC) director awarded $250K in restricted share units - Stock Titan
Bausch Health (BHC) director Sarah Kavanagh receives $250,000 RSU grant - Stock Titan
Bausch Health (NYSE: BHC) director awarded 45,871 RSUs valued at $250,000 - Stock Titan
Director Garcia (BHC) receives $250,000 restricted share grant in Form 4 - Stock Titan
BHC Q1 2026 Earnings: EPS Surprises to the Upside Amidst Operational ExecutionGuidance Downgrade Alert - newsline.com
Bausch Health Cos (BHC) Stock Price, News & Analysis $BHC - MarketBeat
Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading PlayersDompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals - Yahoo Finance
Bausch Health (NYSE: BHC) director sells 24,456 shares under plan - Stock Titan
New Bausch Health (BHC) director Eiry Roberts added as insider on Form 3 - Stock Titan
BHC: Sustained growth, China expansion, and BLCO monetization drive strategic priorities - TradingView
Bausch Health shareholders elect board members and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Bausch Health shareholders elect board members and approve auditor at annual meeting - Investing.com
Shareholders of Bausch Health (NYSE: BHC) approve directors, pay and PwC - Stock Titan
Eiry Roberts to chair Bausch Health science and technology committee - Stock Titan
[144] Bausch Health Companies Inc. SEC Filing - Stock Titan
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. - Investing.com UK
Cannabis Pharmaceuticals Business Research Report 2026: An - GlobeNewswire
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth - Yahoo Finance
Bausch Health rises on Q1 double beat, 2026 guidance - MSN
Bausch Health Companies (BHC) price target decreased by 10.52% to 6.72 - MSN
Dry Eye Products Market Will Generate Booming Growth - openPR.com
BHC Stock Price, Quote & Chart | BAUSCH HEALTH COS INC (NYSE:BHC) - ChartMill
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference - The Globe and Mail
Hear Bausch Health chiefs in live RBC healthcare chat May 20 - Stock Titan
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference - 富途牛牛
Why BauschHealth (BHC) might be the steady performer you need (Technical Weakness) 2026-05-11IV Crush Alert - newsline.com
Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says - Moomoo
Bausch Health Cos (BHC) Earnings Date and Reports 2026 $BHC - MarketBeat
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe – Company Announcement - Financial Times
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging - Seeking Alpha
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):